-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Two New Active Pharmaceutical Ingredients Approved on the Same Day! Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical Receives Approval for Dopamine Hydrochloride and Phloroglucinol Trimethyl Ether APIs
Category:
发布时间：2026-02-25
【概要描述】
As the Spring Festival approaches, good news keeps pouring in. On February 9, Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for its development of dobutamine hydrochloride and phloroglucinol trimethyl ether, officially registering them as active pharmaceutical ingredients for use in marketed dosage forms. Since the beginning of this year, the Group has secured approval for a total of five new products.
With the Spring Festival approaching, good news keeps pouring in. On February 9, Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for its development of dobutamine hydrochloride and phloroglucinol trimethyl ether, officially registering them as active pharmaceutical ingredients for use in marketed dosage forms. Since the beginning of this year, the Group has secured approval for a total of five new products.
According to available information, dobutamine hydrochloride is primarily used to enhance myocardial contractility in acute circulatory failure and for stress echocardiography. Phloroglucinol trimethyl ether (formerly known as trimethylphloroglucinol) is mainly used in the preparation of phloroglucinol injection, which is indicated for acute spastic pain caused by dysfunction of the digestive system and biliary tract; acute spasm-related urethral, bladder, and renal colic; and gynecological spastic pain.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has continuously deepened its integrated “API-plus-formulation” strategic layout. By strengthening R&D innovation and supply-chain collaboration, the Group has established a diversified product portfolio spanning both chemical APIs and finished dosage forms. Currently, the Group boasts 93 API products, with Guangxiang Pharmaceutical accounting for 51 of them. The proportion of specialty APIs is steadily increasing, covering multiple therapeutic areas such as cardiovascular, anti-infective, and central nervous system treatments, thereby continuously injecting strong momentum into the Group’s high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091